Research developed at LNBio in partnership with Boldrini and Unicamp is awarded by Capes
Investigation has identified a mutation related to development and progression of leukemia.
RENAMA board of directors has defined priorities for next year
LNBio is part of the The Network for Alternative Methods to the use of animals.
International conference explores the challenges and opportunities for research & development for neglected diseases
LNBio research represents Brazil in Paris
Solid strategy ensures global recognition of Natura
LNBio is partner of this innovative company.
Meeting will address identification of bioactive compounds
LNBio researchers will give presentation on High Content Screening (HCS) e High Throughput Screening (HTS) on next thursday at IOC/FioCruz, Rio de Janeiro.
Stronger Partnership
FAPESP activity report highlights the SPEC Pilot Program. LNBio is the first beneficiary of this initiative.
LNBio held the IV Proteomics Workshop
Workshop focused on proteomics and mass spectrometry is attended by 120 researchers and students.
Participants of the "Workshop on Drug Design and Neglected Diseases" visit LNBio
Researchers had visited the Bioassays Laboratory (LBE).
Thesis developed at LNBio in partnership with Boldrini won the 'Capes prize for thesis' in biosciences
Research has unveiled a new genetic mutation in leukemia which may help to design future targeted therapies.
LNBio: leading centre of biotechnology in Latin America
Laboratory is highlighted in a newspaper article about biotechnology.